Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dicitratobismuthate→

Dicitratobismuthate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
57644-54-9
Molecular formula
K3Bi(C6H5O7)2
Molecular weight
704.47 g/mol
Drug class
Bismuth tripotassium dicitrate (colloidal bismuth subcitrate)gastrointestinal mucosal protectant
Mechanism of action
Acts through several local gastrointestinal mechanisms: forms a protective layer over ulcerated mucosa, increases mucus glycoprotein secretion, inhibits peptic activity and has activity against Helicobacter pylori. Its effects are not adequately described by a single molecular target.
Indications / reported uses
  • Treatment of gastric and duodenal ulcers
  • Part of combination regimens for Helicobacter pylori eradication, according to the current local product information and antimicrobial regimen

Sources: NCI Drug Dictionary — Bismuth subcitrate · PubMed — The mode of action of colloidal bismuth subcitrate · PubMed — Studies on the mechanism of action of colloidal bismuth subcitrate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dicitratobismuthate Environmental Risk Assessment (ERA) (the Dicitratobismuthate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.